Cosmetic cross-reference Noindex: medium evidence

Isorhamnetin

CAS 480-19-3

Isorhamnetin (CAS 480-19-3) is a pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Isorhamnetin
CAS Number
480-19-3
UNII
07X3IB4R4Z
InChIKey
IZQSVPBOUDKVDZ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL379064
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- IC50 18750.96 nM 25 -
- Ki 3437.2444444444445 nM 9 -
- Potency 33050.614285714284 nM 5 -
- EC50 26.2 ug 1 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Isorhamnetin used for in pharmaceutical contexts?

Isorhamnetin (CAS 480-19-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Isorhamnetin?

No adverse-event association or SIDER side-effect rows are rendered for Isorhamnetin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Isorhamnetin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Isorhamnetin with EU status "permitted".

What clinical phase is Isorhamnetin in?

No phase 1-4 clinical development badge is rendered for Isorhamnetin because the matched compound identifier rows do not contain a max-phase value.